irinotecan

P2/3, N=163, Recruiting, Uppsala University | Not yet recruiting --> Recruiting

A paclitaxel, ifosfamide, and cisplatin-based regimen achieves response rates around 65%...Compared to standard chemotherapy (e.g. cisplatin, 5-FU, ifosfamide, irinotecan), treatment with romidepsin, quisinostat (HDAC inhibitors (i)), palbociclib (CDK4/6i), or 17-AAG and PU-H71 (HSP90i) reduced cell viability, induced apoptosis, and led to G2 / M cell cycle arrest in most PeCa cells. This research underscores the therapeutic potential of using HDAC, CDK4/6, and HSP90 inhibitors for PeCa management and reveals additional promising targets and biomarkers for future strategies.

Multiple chemotherapy regimens (ifosfamide, carboplatin, and etoposide; and doxorubicin, vincristine, cyclophosphamide, and cisplatin) demonstrated limited efficacy. Subsequent treatment with alternating albumin-paclitaxel, gemcitabine, ifosfamide, and etoposide/cyclophosphamide, irinotecan, and vincristine chemotherapy combined with anlotinib and cranial radiotherapy achieved disease stabilization, with no subsequent progression observed during follow-up. This case highlights the aggressive nature and chemoresistance of the mesenchymal components of HB, emphasizing the need for novel therapeutic approaches that incorporate targeted agents.

The CT-IBS stratified patients into three distinct prognostic groups (median overall survival 27.3 vs. 17.8 vs. 8.6 months; p < 0.001; area under the curve 0.703). Integrating dynamic inflammatory changes with liver tumor burden yields a simple, reproducible classification that may support risk stratification, patient selection, and post-treatment surveillance after irinotecan-eluting bead chemoembolization for colorectal liver metastases.

Although 5-fluorouracil-induced animal models of oral mucositis are well established, irinotecan, widely used for colorectal, lung, and pancreatic cancers, has also been associated with oral mucosal injury; however, no standardized preclinical model exists. HST, particularly when administered prophylactically, exhibited better efficacy than dexamethasone, potentially through modulation of inflammatory responses and attenuation of oxidative stress. This model may facilitate further mechanistic studies and the development of preventive strategies for chemotherapy-induced oral mucositis.

P4, N=36, Suspended, University of Chicago | Recruiting --> Suspended

P1/2, N=120, Not yet recruiting, LARKSPUR BIOSCIENCES, INC.

CD expression was verified at the transcript level and by functional 5-FC-to-5-fluorouracil (5-FU) conversion, whereas CE2 expression was verified by transcript analysis and immunoblotting. Within the constraints of our in vitro assays and subcutaneous xenograft model, CE2/CPT-11 demonstrated stronger efficacy outcomes than CD/5-FC. Mechanistic attribution to intratumoral SN-38 exposure should be confirmed by direct metabolite measurements in future studies.

P2, N=44, Completed, IRCCS San Raffaele | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025 | Recruiting --> Completed

P2, N=130, Completed, Institut de Cancérologie de Lorraine | Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Dec 2025

Also, particular emphasis is placed on how CAF-derived exosomes modulate cellular responses to cytotoxic agents, containing 5-fluorouracil, oxaliplatin, irinotecan, and radiotherapy. These exosomes alter DNA damage responses, ferroptosis, apoptosis, oxidative stress, and survival signaling, thereby reshaping the toxicity profile of anticancer treatments. Understanding these exosome-mediated mechanisms is critical for overcoming chemoresistance and radiosurvival in CRC.